Exact Sciences’ Precision Oncology portfolio of genomic solutions aims to:

Transform cancer care by providing valuable insights across the stages of diagnosis and treatment
Enable patients to take a more active role in their care
Make it easy for providers to order tests, interpret results, and personalize medicine by applying real-world evidence and guideline recommendations

Patients
receive clarity into their diagnosis

Practices
uncover actionable insights when they need it

Physicians
find support for personalized medicine

Experience genomic intelligence across the stages of oncology care.

Our Shared Goal: Changing Lives, Together

Exact Sciences is changing the way we think about assessing and treating cancer. But lasting change does not happen alone. Together, we can improve the future of cancer care because Precision Oncology is:

  • Dedicated to eradicating cancer and the suffering it causes through tests that help prevent cancer, assess risk, and guide treatment
  • A trusted partner for providers to serve newly diagnosed and advanced stage cancer patients by expanding our product portfolio
  • A supplier of timely genomic information backed by rigorous clinical evidence and remarkable service at every step in the treatment process

Our commitment to you is simple: Provide actionable genomic information. Inform life-changing treatment decisions. Support you and your patients across the stages of cancer care.

Our Portfolio

Genomic tests in breast, colon, prostate, and other advanced solid tumor cancers that provide the Exactionable genomic information physicians have come to trust.

Select a cancer type to learn more about the Precision Oncology tests in those areas:

Our Precision Oncology Focus

The Exact portfolio of genomic tests focuses on breast, prostate, lung, and colorectal cancers, as well as other solid tumors. The Precision Oncology portfolio builds on this by connecting patients to the right treatment based on the right information.

Our advanced clinical capabilities all align to support the priorities facing health systems and include:

  • Exemplary lab infrastructure
  • Strong academic collaboration
  • Rigorous commitment to evidence generation

We are committed to offering a portfolio of products that provides better prognostic and treatment guidance information for patients now and into the future.

Our Unique Approach

Since the beginning, we have been focused on developing partnerships with elite academic institutions, medical societies, and advocacy groups to develop our products. Generating high-quality clinical evidence represents our enduring commitment to cancer care, while ensuring access and resources for patients and their caregivers is at the heart of everything we do.

Our Shared Future

  Genomic Intelligence Enhanced Experiences Trusted Partner
Our Commitment to You Help you apply advanced genomic science to reveal the unique biology of each patient’s condition. Deliver exceptional user experience while continually advancing tests that are easy to interpret. Serve as an innovator in cancer diagnostics, predicting and solving the latest problems in oncology.
Benefits of Our Tests Apply personalized insights for greater confidence in treatment decisions.

Receive timely, accurate results for faster decisions.

Inform treatment decisions before, during, and after treatment with therapy selection and recurrence risk genomic information.
Enable an efficient ordering and result-gathering process with a convenient physician portal.

Use interactive report guides and easy-to-read results to make informed decisions.

Provide patients with important billing and coverage information, along with access to results and ordering details all in one place.
Testing options across the stages of cancer care, from diagnosis through progression or remission.

Shared confidence through exemplary Oncotype DX® tests with strong supporting evidence and proven clinical utility.

Feel confident using tests with over 1.5M patients tested and our ongoing commitment to provide patients the information they need to make treatment decisions.

20+

years of experience

1.5 million

patients benefitted

90

countries served